文献速递浆细胞疾病造血干细胞移植与细胞治疗

GPRC5D CAR T细胞(OriCAR-017)治疗复发或难治性多发性骨髓瘤患者(POLARIS):一项首次人体、单中心、单臂、1期试验

GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial.
PubMed 文献 · Lancet Haematol · 2023-01-01

POLARIS是一项首次人体、单中心、单臂1期试验,在复发或难治性多发性骨髓瘤患者中评估GPRC5D靶向CAR T细胞OriCAR-017的安全性和活性。9例患者接受剂量递增(1×10^6、3×10^6、6×10^6 CAR T细胞/kg),未观察到剂量限制性毒性,推荐2期剂量为3×10^6 CAR T细胞/kg。10例接受治疗患者中10例(100%)获总体缓解,6例(60%)达严格完全缓解,4例(40%)达非常好的部分缓解。

要点

  • 未观察到剂量限制性毒性,最大耐受剂量未确定,推荐2期剂量为3×10^6 CAR T细胞/kg。
  • 10例可评估患者总体缓解率100%,其中严格完全缓解60%、非常好的部分缓解40%。
  • 所有患者发生细胞因子释放综合征(90%为1级、10%为2级),未报告神经毒性。

核心结论

  • 本研究结果提示GPRC5D是多发性骨髓瘤免疫治疗的一个活跃靶点。
  • GPRC5D靶向CAR T细胞疗法是复发或难治性多发性骨髓瘤有前景的治疗方式,值得进一步测试。

研究设计与样本

  • POLARIS是一项首次人体、单中心、单臂、1期试验,在浙江大学医学院附属第一医院(中国杭州)开展。
  • 纳入18-75岁、ECOG体能状态0-2、骨髓浆细胞GPRC5D表达大于20%或免疫组化GPRC5D阳性、且既往至少接受过三线治疗(包括蛋白酶体抑制剂、免疫调节药物和化疗)的复发或难治性多发性骨髓瘤成人患者。
  • 剂量递增阶段患者连续接受单次静脉OriCAR-017,剂量为1×10^6、3×10^6或6×10^6 CAR T细胞/kg;扩展阶段接受推荐2期剂量。
  • 2022年5月1日因COVID-19疫情提前终止扩展阶段招募。
  • 主要终点为安全性、最大耐受剂量和推荐2期剂量;安全性和活性分析纳入所有接受OriCAR-017的患者。

主要发现

  • 未观察到剂量限制性毒性,因此最大耐受剂量未确定;基于安全性和初步活性,推荐2期剂量设为3×10^6 CAR T细胞/kg,扩展阶段1例患者接受了该剂量。
  • 接受治疗患者中5例(50%)为女性、5例(50%)为男性,均为中国人;5例(50%)既往接受过BCMA靶向CAR T细胞治疗。
  • 中位随访238天(IQR 182-307);无严重不良事件和治疗相关死亡。
  • 最常见的3级或更严重不良事件为血液学毒性:中性粒细胞减少10例(100%)、血小板减少9例(90%)、白细胞减少9例(90%)、贫血7例(70%)。
  • 所有患者发生细胞因子释放综合征(9例[90%]为1级,1例[10%]为2级);未报告神经毒性;10例(100%)患者获总体缓解,其中6例(60%)达严格完全缓解、4例(40%)达非常好的部分缓解。

局限性

  • 扩展阶段招募于2022年5月1日因COVID-19疫情提前终止。
  • 研究为单中心、单臂设计。
  • 样本量小(9例进入剂量递增,共10例接受治疗)。
  • 中位随访238天(IQR 182-307),随访时间有限。
  • 作者结论认为该疗法值得进一步测试。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA) has shown activity in treating relapsed or refractory multiple myeloma; however, relapse is still common, and new targets are needed. We aimed to assess the activity and safety profile of G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma. METHODS: POLARIS was a first-in-human, single-centre, single-arm, phase 1 trial of GPRC5D-targeted CAR T cells (OriCAR-017) done at the First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China. Eligible patients were adults aged 18-75 years with a diagnosis of relapsed or refractory multiple myeloma and an ECOG performance status of 0-2, had GPRC5D expression in bone marrow plasma cells greater than 20% or were positive for GPRC5D by immunohistochemistry, and had received at least three previous lines of treatment including proteasome inhibitors, immunomodulatory drugs, and chemotherapy. Patients were consecutively assigned to receive a single dose of intravenous OriCAR-017 at 1 × 106 CAR T cells per kg, 3 × 106 CAR T cells per kg, or 6 × 106 CAR T cells per kg in the dose-escalation phase. In the expansion phase, patients received the recommended phase 2 dose. Recruitment to the expansion phase terminated early due to the COVID-19 pandemic on May 1, 2022. The primary endpoints were safety, the maximum tolerated dose and the recommended phase 2 dose. Safety and activity analyses included all patients who received OriCAR-017. This trial is registered with ClinicalTrials.gov, NCT05016778. This trial has been completed and is entering long-term follow-up. FINDINGS: Between June 9, 2021, and Feb 28, 2022, we recruited 13 patients for inclusion into the study. One patient was excluded because of GPRC5D negativity and two patients discontinued after apheresis because of rapid progression. Nine patients were assigned to the dose escalation phase (three received 1 × 106 CAR T cells per kg, three received 3 × 106 CAR T cells per kg, and three received 6 × 106 CAR T cells per kg). The maximum tolerated dose was not identified, because no dose-limiting toxic effects were observed. On the basis of safety and preliminary activity, the recommended phase 2 dose was set at 3 × 106 CAR T cells per kg, which was received by one additional patient in the dose expansion phase. Five patients (50%) were female, five (50%) were male, and all were Chinese. Five patients (50%) were previously treated with BCMA-targeted CAR T-cell therapy. Median follow-up was 238 days (IQR 182-307). There were no serious adverse events and no treatment-related deaths. The most common grade 3 or worse adverse events were haematological, including neutropenia (ten [100%] of ten patients), thrombocytopenia (nine [90%]), leukopenia (nine [90%]), and anaemia (seven [70%]). All patients had cytokine release syndrome (nine [90%] grade 1 and one [10%] grade 2). No neurological toxic effects were reported. Ten (100%) of ten patients had an overall response, of whom six (60%) had a stringent complete response and four (40%) had very good partial response. Two patients discontinued due to disease progression (one GPRC5D-positive patient in the middle-dose group and one GPRC5D-negative patient in the low-dose group). INTERPRETATION: The results of this study suggest that GPRC5D is an active target for immunotherapy in multiple myeloma. GPRC5D-targeted CAR T-cell therapy is a promising treatment modality for patients with relapsed or refractory multiple myeloma and deserves further testing. FUNDING: OriCell Therapeutics.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Zhang M, Wei G, Zhou L, et al. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2023. PMID: 36725117. doi:10.1016/S2352-3026(22)00372-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。